Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neurofibromatosis 2”

95 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 95 results

Testing effectiveness (Phase 2)Ended earlyNCT03095248
What this trial is testing

Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors

Who this might be right for
Neurofibromatosis 2Vestibular SchwannomaMeningioma+2 more
Children's Hospital Medical Center, Cincinnati 10
Testing effectiveness (Phase 2)Study completedNCT01207687
What this trial is testing

Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)

Who this might be right for
Vestibular SchwannomaNeurofibromatosis Type 2
National Cancer Institute (NCI) 14
Testing effectiveness (Phase 2)Study completedNCT02839720
What this trial is testing

Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma

Who this might be right for
Cutaneous NeurofibromaNeurofibromatosis Type 1Optic Nerve Glioma
National Cancer Institute (NCI) 11
Testing effectiveness (Phase 2)Study completedNCT02831257
What this trial is testing

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

Who this might be right for
Neurofibromatosis 2Meningioma
Massachusetts General Hospital 18
Testing effectiveness (Phase 2)Study completedNCT01767792
What this trial is testing

Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas

Who this might be right for
Neurofibromatosis Type 2Progressive Vestibular Schwannomas
University of Alabama at Birmingham 22
Testing effectiveness (Phase 2)Study completedNCT05005845
What this trial is testing

NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

Who this might be right for
Cutaneous NeurofibromaNeurofibromatosis 1
NFlection Therapeutics, Inc. 199
Testing effectiveness (Phase 2)Study completedNCT03433183
What this trial is testing

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Who this might be right for
Malignant Peripheral Nerve Sheath TumorsNeurofibromatosis 1
Sarcoma Alliance for Research through Collaboration 21
Early research (Phase 1)Looking for participantsNCT06961565
What this trial is testing

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

Who this might be right for
NF1 MutationNeurofibroma PlexiformNeurofibroma, Plexiform+2 more
Pasithea Therapeutics Corp. 56
Testing effectiveness (Phase 2)Looking for participantsNCT06553365
What this trial is testing

Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors

Who this might be right for
Nerve Sheath Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 30
Early research (Phase 1)Study completedNCT02952937
What this trial is testing

Bioequivalence Study of Two Formulations of Pregabalin CR(Controlled-release) Table 300 mg

Who this might be right for
Healthy
GL Pharm Tech Corporation 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT05521048
What this trial is testing

Doxycycline in Cutaneous Schwannoma (NF2)

Who this might be right for
Neurofibromatosis Type 2
Massachusetts Eye and Ear Infirmary 19
Testing effectiveness (Phase 2)Ended earlyNCT01345136
What this trial is testing

Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

Who this might be right for
Neurofibromatosis Type 2Neuroma, Acoustic
Jonsson Comprehensive Cancer Center 4
Testing effectiveness (Phase 2)WithdrawnNCT02986919
What this trial is testing

Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors

Who this might be right for
Peripheral Nerve Tumors
University of Texas Southwestern Medical Center
Very early researchStudy completedNCT00863122
What this trial is testing

Concentration and Activity of Lapatinib in Vestibular Schwannomas

Who this might be right for
Vestibular SchwannomaNF2Neurofibromatosis 2+2 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 26
Testing effectiveness (Phase 2)Active Not RecruitingNCT03363217
What this trial is testing

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Who this might be right for
Low-grade GliomaPlexiform NeurofibromaCentral Nervous System Glioma
St. Justine's Hospital 114
Testing effectiveness (Phase 2)Study completedNCT02104323
What this trial is testing

Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Who this might be right for
Vestibular SchwannomaNeurofibromatosis Type 2
Beijing Tiantan Hospital 20
Not applicableLooking for participantsNCT05685836
What this trial is testing

89Zr-Bevacizumab PET/CT Imaging in NF2 Patients

Who this might be right for
Neurofibromatosis 2
Leiden University Medical Center 15
Early research (Phase 1)Study completedNCT02955472
What this trial is testing

Bioequivalence Study of Two Formulations of Pregabalin CR (Controlled-release) Table 150 mg

Who this might be right for
Healthy
GL Pharm Tech Corporation 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT06287463
What this trial is testing

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Who this might be right for
Advanced Solid TumorRAF MutationRAS Mutation+7 more
Deciphera Pharmaceuticals, LLC 140
Testing effectiveness (Phase 2)Ended earlyNCT02177825
What this trial is testing

Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas

Who this might be right for
Plexiform Neurofibromas
St. Justine's Hospital 5
Load More Results